Codexis reports Q1 EPS (10c), consensus (10c)

Reports Q1 revenue $15.25M, consensus $14.53M. “Next week Codexis (CDXS) will present new data at the TIDES USA annual meeting demonstrating how the ECO Synthesis Manufacturing Platform enables control over phosphorothioate stereochemistry. Defined stereochemistry confers overall improved product quality and has the potential to deliver increased potency, a step beyond conventional manufacturing technologies,” said Alison Moore, President and Chief Executive Officer of Codexis. “We finished the first quarter in a strong financial position with $65.1 million in cash, which we believe remains on track to fund anticipated operations through the end of 2027.”